Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration

Clinical and Experimental Allergy

Volumn 28, Issue 7, 1998, Pages 868-875

  Proud, D ^a,b   Reynolds, C J ^a   Lichtenstein, L M ^a   Kagey Sobotka, A ^a   Togias, A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

2 adrenergic agonist; Asthma; Cytokines; Glands; Mast cells; Rhinitis; Salmeterol; Vascular permeability

Indexed keywords

ALLERGEN; SALMETEROL;

ALLERGIC REACTION; ALLERGIC RHINITIS; ALLERGY; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOMODULATION; MAST CELL DEGRANULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SNEEZING; SYMPTOMATOLOGY;

ADMINISTRATION, INTRANASAL; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ASTHMA; CAPILLARY PERMEABILITY; CELL COUNT; CYTOKINES; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTAMINE RELEASE; HUMANS; MALE; MAST CELLS; MURAMIDASE; NASAL LAVAGE FLUID; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 0031840982     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1998.00335.x     Document Type: Article

References (38)

1. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study:comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306:1034-7.
2. 2 adrenoreceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 1988; 43:674-8.
3. Butchers PR, Vardey CJ, Johnson M. Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br J Pharmacol 1991; 104:672-6.
4. Twentyman OP, Finnerty JP, Harris A, Palmer J, Holgate ST. Protection against allergen-induced asthma by salmeterol. Lancet 1990; 336:1338-42.
5. Whelan CJ, Johnson M. Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin. Br J Pharmacol 1992; 105:831-8.
6. Naclerio RM, Meier HC, Kagey-Sobotka A et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983; 128:597-602.
7. Majchel AM, Baroody F, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. Effect of oxymetazoline on the early response to nasal challenge with antigen. J Allergy Clin Immunol 1993; 92:767-70.
8. Churchill L, Pongracic JA, Reynolds CJ, Naclerio RM, Proud D. Pharmacology of nasal provocation with bradykinin: studies of tachyphylaxis, cyclooxygenase inhibition, alpha-adrenergic stimulation, and receptor subtype. Int Arch Allergy Appl Immunol 1991; 95:322-31.
9. Svensson C, Pipkorn U, Alkner U, Baumgarten CR, Persson CGA. Topical vasoconstrictor (oxymetazoline) does not affect histamine-induced mucosal exudation of plasma in human nasal airways. Clin Exp Allergy 1992; 22:411-6.
10. Proud D, Gwaltney JM Jr, Hendley JO, Dinarello CA, Gillis S, Schleimer RP. Increased levels of interleukin-1 are detected in nasal secretions of volunteers during experimental rhinovirus colds. J Infect Dis 1994; 169:1007-13.
11. Naclerio RM, Hubbard W, Lichtenstein LM, Kagey-Sobotka A, Proud D. Origin of late phase histamine release. J Allergy Clin Immunol 1996; 98:721-3.
12. Siraganian RP. Refinements in the automated fluorometric histamine analysis system. J Immunol Meth 1975; 7:283-90.
13. 2, and prostacyclin from human lung parenchyma. Am Rev Respir Dis 1981; 124:402-6.
14. Proud D, Bailey GS, Naclerio RM et al. Tryptase and histamine as markers to evaluate mast cell activation during the responses to nasal challenge with allergen, cold, dry air, and hyperosmolar solutions. J Allergy Clin Immunol 1992; 89:1098-110.
15. Riccio MM, Proud D. Evidence that enhanced nasal reactivity to bradykinin in patients with symptomatic allergy is mediated by neural reflexes. J Allergy Clin Immunol 1996; 97:1252-63.
16. Riccio MM, Reynolds CJ, Hay DW, Proud D. Effects of intranasal administration of endothelin-1 to allergic and non-allergic individuals. Am J Respir Crit Care Med 1995; 152:1757-64.
17. Svensson C, Greift L, Andersson M, Alkner U, Grönnenberg R, Persson CGA. Antiallergic actions of high topical doses of terbutaline in human nasal airways. Allergy 1995; 50:884-90.
18. Bende M, Loth S. Vascular effects of topical oxymetazoline on human nasal mucosa. J Laryngol Otol 1986; 100:285-8.
19. Peters SP, Schulman ES, Schleimer RP et al. Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung tissue fragments. Am Rev Respir Dis 1982; 126:1034-9.
20. Church MK, Hiroi J. Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol 1987; 90:421-9.
21. Lichtenstein LM, Margolis S. Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science 1968; 161:902-3.
22. Howarth PH, Durham SR, Lee TH et al. Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator response to allergen bronchial provocation in asthma. Am Rev Respir Dis 1985; 132:986-92.
23. Peters SP, MacGlashan DW Jr, Schulman ES et al. Arachidonic acid metabolism in purified human lung mast cells. J Immunol 1984; 132:1972-9.
24. Barnes PJ, Basbaum CB. Mapping of adrenergic receptors in the trachea by autoradiography. Exp Lung Res 1983; 5:183-92.
25. Tom-Moy M, Basbaum CB, Nadel JA. Localization and release of lysozyme from ferret trachea: effects of adrenergic and cholinergic drugs. Cell Tissue Res 1983; 228:549-62.
26. Mullol J, Raphael GD, Lundgren JD et al. Comparison of human nasal mucosal secretion in vivo and in vitro. J Allergy Clin Immunol 1992; 89:584-92.
27. Sim TC, Grant JA, Hilsmeier KA, Fukuda Y, Alam R. Pro-inflammatory cytokines in nasal secretions of allergic subjects after challenge. Am J Respir Crit Care Med 1994; 149:339-44.
28. Sim TC, Reece LM, Hilsmeier KA, Grant JA, Alam R. Secretion of chemokines and other cytokines in allergen-induced nasal responses: inhibition by topical steroid treatment. Am J Respir Crit Care Med 1995; 152:927-33.
29. Kuna P, Lazarovich M, Kaplan AP. Chemokines in seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97:104-12.
30. Persson CGA, Ekman M, Erjefält I. Vascular anti-permeability effects of β-receptor agonists and theophylline in the lung. Acta Pharmacol Toxicol 1979; 44:216-20.
31. Erjefält I, Persson CGA. Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways. Am Rev Respir Dis 1991; 144:788-91.
32. Bolton PB, LeFevre P, McDonald DM. Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways. Am J Respir Crit Care Med 1997; 155:1428-35.
33. 2-adrenoreceptor agonist and terbutaline. Allergy 1990; 45:340-6.
34. Basran GS, Paul W, Morley J, Turner-Warwick M. Adrenoreceptor agonist inhibition of the histamine induced cutaneous response in man. Br J Dermatol 1982; 107 (Suppl. 23):140-2.
35. Persson CGA. Role of plasma exudation in asthmatic airways. Lancet 1986; ii:1126-9.
36. Erjefält I, Persson CGA. Pharmacologic control of plasma exudation into tracheobronchial airways. Am Rev Respir Dis 1991; 143:1008-14.
37. Pare PD, Godden DJ. Airway edema. In: Crystal RG, West JB, Barnes PJ, Chernial NS, Weibel ER, eds The Lung: Scientific Foundations. New York: Raven Press, 1991:987-94.
38. Yager D, Butler JP, Bastacky J, Israel G, Smith G, Drazen JM. Amplification of airway constriction due to liquid filling or airway interstices. J Appl Physiol 1989; 66:2873-84.